enGene Therapeutics Inc. ENGN
1.62 USD +0.17 (+11.72%)
At closeNov 3, 2026, 4:04 PM EST
1.60 -0.02 -1.23%
After hours · Nov 3, 4:04 PM ET
1.45 Day range 1.62
1.40 52-week range 12.25
- YTD
- -82.06%
- 1 year
- -76.59%
- Market cap
- 108.57M
- EPS (ttm)
- -2.07
- Shares out
- 50.98M
- Forward P/E
- -3.53
- YTD return
- -82.06%
- 1-year return
- -76.59%
- Volume
- 937.12K
- Avg volume
- 758.86K
- Open
- 1.47
- Previous close
- 1.45
- Day's range
- 1.45 – 1.62
- 52-week range
- 1.40 – 12.25
- Beta
- -0.76
- Analysts
- Strong Buy
- Price target
- 27.00 (+1566.7%)
YTD -7.32 (-82.71%)
Key statistics
- Enterprise value
- 30.70M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -23.58M
- Total cash
- 257.68M
- Total debt
- 24.86M
- Return on equity
- -123.06%
- Short % of float
- 2.00%
- 50-day average
- 8.10
- 200-day average
- 10.01
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 27.00 +1566.7% upside
Now 1.62
- Target (low)
- 16.00
- Target (mean)
- 27.00
- Target (high)
- 37.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy4
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.3825.
Financials — quick view
ENGN Revenue — quarterly 0
ENGN Net income — quarterly -32.50M
ENGN EPS — quarterly -0.47
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Dec 23, 2024 | HC Wainwright & Co. | init | — | Buy |
| Dec 6, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Nov 27, 2024 | Raymond James | init | — | Outperform |
| Nov 18, 2024 | JMP Securities | init | — | Market Outperform |
| Sep 24, 2024 | Oppenheimer | reit | Outperform | Outperform |
About enGene Therapeutics Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). The company is based in Montreal, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- engene.com
News
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path 
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript 
enGene to Host KOL Webinar on October 15, 2026 
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript 
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market 
Citizens Reiterates Market Perform on enGene Therapeuticsto Market Perform - enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update 
enGene to Participate in Upcoming Investor Conferences 
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
Your note
Sign in to keep a note on ENGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRUNK GERALD A | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Feb 19, 2024 | 0 |
| CHEUNG ANTHONY TZEYEW | Chief Technology Officer | Conversion of Exercise of derivative security | Mar 17, 2024 | 102,873 |
| COOPER RONALD HAROLD WILFRED | Chief Executive Officer | Purchase | Sep 26, 2024 | 10,000 |
| FONDS DE SOLIDARITE DES TRAVAILLEURS DU | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 21, 2024 | 3,036,150 |
| FORBION GROWTH SPONSOR FEAC I B.V. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 26, 2023 | 0 |
| GLICKMAN RICHARD M | Director | Conversion of Exercise of derivative security | May 27, 2024 | 24,675 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fcpm III Services B.v. | 17.02% | 8,677,951 | 51.72M | Sep 29, 2024 |
| VR Adviser, LLC | 7.00% | 3,565,841 | 21.25M | Sep 29, 2024 |
| Blue Owl Capital Holdings LP | 6.00% | 3,058,969 | 18.23M | Sep 29, 2024 |
| Deep Track Capital, Lp | 5.12% | 2,607,633 | 15.54M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 4.57% | 2,329,768 | 13.89M | Sep 29, 2024 |
| BVF Inc. | 4.42% | 2,251,037 | 13.42M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 0.53% | 272,359 | 1.62M | Jul 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 27,516 | 164.00K | Oct 30, 2024 |
| Northern Small Cap Core Fund | 0.02% | 11,000 | 65.56K | Sep 29, 2024 |